PE20220139A1 - Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar - Google Patents
Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiarInfo
- Publication number
- PE20220139A1 PE20220139A1 PE2021001329A PE2021001329A PE20220139A1 PE 20220139 A1 PE20220139 A1 PE 20220139A1 PE 2021001329 A PE2021001329 A PE 2021001329A PE 2021001329 A PE2021001329 A PE 2021001329A PE 20220139 A1 PE20220139 A1 PE 20220139A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- cyano
- hydroxy
- hydrogen
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000001730 Familial dysautonomia Diseases 0.000 abstract 1
- 201000001638 Riley-Day syndrome Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- -1 thieno[3,2-b]pyridine derivative compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805283P | 2019-02-13 | 2019-02-13 | |
| PCT/US2020/017430 WO2020167628A1 (en) | 2019-02-13 | 2020-02-10 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220139A1 true PE20220139A1 (es) | 2022-01-27 |
Family
ID=69960696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001329A PE20220139A1 (es) | 2019-02-13 | 2020-02-10 | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12384797B2 (enExample) |
| EP (1) | EP3924049B1 (enExample) |
| JP (1) | JP7587511B2 (enExample) |
| KR (1) | KR102907028B1 (enExample) |
| CN (1) | CN113795304A (enExample) |
| AU (1) | AU2020222881C1 (enExample) |
| BR (1) | BR112021015853A2 (enExample) |
| CA (1) | CA3129067A1 (enExample) |
| CL (1) | CL2021002137A1 (enExample) |
| CO (1) | CO2021010598A2 (enExample) |
| EA (1) | EA202192170A1 (enExample) |
| IL (1) | IL285399B2 (enExample) |
| MX (1) | MX2021009667A (enExample) |
| PE (1) | PE20220139A1 (enExample) |
| SG (1) | SG11202108519TA (enExample) |
| UA (1) | UA129890C2 (enExample) |
| WO (1) | WO2020167628A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| AU2020222881C1 (en) | 2019-02-13 | 2026-01-22 | Ptc Therapeutics, Inc. | Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia |
| KR20220113700A (ko) * | 2019-12-12 | 2022-08-16 | 피티씨 테라퓨틱스, 인크. | 가족성 자율신경실조증 치료를 위한 화합물 |
| WO2021231571A1 (en) | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| CA3204868A1 (en) * | 2021-01-14 | 2022-07-21 | Charbel MOUSSA | Usp13 inhibitors and methods of use thereof |
| CN112920053B (zh) * | 2021-02-01 | 2022-07-01 | 暨明医药科技（苏州）有限公司 | 一种手性α-甲基芳乙胺的制备方法 |
| US20240051968A1 (en) | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| EP4288059A4 (en) * | 2021-02-05 | 2025-01-08 | PTC Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| US20240041886A1 (en) * | 2021-02-05 | 2024-02-08 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| TW202313623A (zh) | 2021-06-03 | 2023-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 具有整合酶抑制活性的吡啶酮化合物及其藥用用途 |
| CA3231007A1 (en) * | 2021-09-07 | 2023-03-16 | Scott J. Barraza | Methods for treating neurogenerative diseases |
| EP4426702A1 (en) * | 2021-11-04 | 2024-09-11 | Skyhawk Therapeutics, Inc. | Condensed-pyrazine amine derivatives for treating sca3 |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| EP4514807B1 (en) | 2022-04-27 | 2025-12-17 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20260027118A1 (en) | 2022-05-12 | 2026-01-29 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| CN119997954A (zh) * | 2022-06-22 | 2025-05-13 | Ptc医疗公司 | 用于治疗脊髓小脑性共济失调3型的化合物 |
| EP4568962A2 (en) * | 2022-08-09 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| JP3126541B2 (ja) | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| NZ335823A (en) | 1997-04-22 | 2001-06-29 | Neurocrine Biosciences Inc | Thiophenopyridines, preparation as CRF receptor antagonists |
| SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2005007083A2 (en) | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| WO2005033290A2 (en) | 2003-10-03 | 2005-04-14 | The General Hospital Corporation | Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders |
| JP2009007341A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2014663A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
| KR101616140B1 (ko) | 2008-03-05 | 2016-04-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환 화합물 |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| US20130209549A1 (en) | 2010-07-21 | 2013-08-15 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
| US20130317045A1 (en) | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EA025186B1 (ru) | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| AU2014214561C1 (en) | 2013-02-11 | 2019-01-17 | Mitokinin, Inc. | Compositions and methods for treating neurodegenerative diseases |
| EP2964654A4 (en) | 2013-03-07 | 2016-08-10 | Glaxosmithkline Llc | THIEN [3,2-D] PYRIMIDIN-6-CARBOXAMIDE AND ANALOGUE AS SIRTUIN MODULATORS |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| US9879014B2 (en) * | 2013-07-12 | 2018-01-30 | Kyoto University | Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease |
| WO2015053624A2 (en) | 2013-10-07 | 2015-04-16 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Antisense oligonucleotide directed removal of proteolytic cleavage sites, the hchwa-d mutation, and trinucleotide repeat expansions |
| KR102390370B1 (ko) | 2014-02-12 | 2022-04-26 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| CA3199430A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
| BR122023023802A2 (pt) | 2015-04-29 | 2023-12-26 | Janssen Pharmaceutica Nv | Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| WO2017053781A1 (en) | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| EP3494229B1 (en) | 2016-08-03 | 2023-10-25 | Meiragtx UK II Limited | High throughput cell-based screening for aptamers |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| CN110312528B (zh) | 2017-02-20 | 2022-02-18 | 国立大学法人京都大学 | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 |
| IL274702B2 (en) | 2017-11-27 | 2026-04-01 | Coda Biotherapeutics Inc | Compounds and methods for neurological diseases |
| US12503467B2 (en) | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| CN109819066A (zh) | 2019-01-31 | 2019-05-28 | 平安科技（深圳）有限公司 | 一种基于地理位置的智能解析域名方法及装置 |
| AU2020222881C1 (en) | 2019-02-13 | 2026-01-22 | Ptc Therapeutics, Inc. | Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| EP3929185A4 (en) | 2019-02-19 | 2023-02-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| WO2020245233A1 (en) | 2019-06-06 | 2020-12-10 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
| KR102537214B1 (ko) | 2019-11-26 | 2023-05-31 | 주식회사 고영테크놀러지 | 자기 공명 이미지들에서 정중시상 평면을 결정하기 위한 방법 및 장치 |
| KR20220113700A (ko) | 2019-12-12 | 2022-08-16 | 피티씨 테라퓨틱스, 인크. | 가족성 자율신경실조증 치료를 위한 화합물 |
| US20230117831A1 (en) | 2020-01-08 | 2023-04-20 | The Broad Institute, Inc. | Multi-functional chimeric molecules |
| US20240051968A1 (en) | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| EP4288059A4 (en) | 2021-02-05 | 2025-01-08 | PTC Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| WO2022169864A1 (en) | 2021-02-05 | 2022-08-11 | Ptc Therapeutics Inc. | Methods for treating spinocerebellar ataxia type 3 |
| US20240024490A1 (en) | 2021-04-09 | 2024-01-25 | The Broad Institute, Inc. | Bifunctional molecules for selective modification of target substrates |
| JP2024533264A (ja) | 2021-09-07 | 2024-09-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 神経原性疾患を処置するための方法 |
| MX2024002886A (es) | 2021-09-07 | 2024-05-24 | Ptc Therapeutics Inc | Metodos para tratar enfermedades neurodegenerativas. |
| CA3231007A1 (en) | 2021-09-07 | 2023-03-16 | Scott J. Barraza | Methods for treating neurogenerative diseases |
| EP4426702A1 (en) | 2021-11-04 | 2024-09-11 | Skyhawk Therapeutics, Inc. | Condensed-pyrazine amine derivatives for treating sca3 |
| CN119997954A (zh) | 2022-06-22 | 2025-05-13 | Ptc医疗公司 | 用于治疗脊髓小脑性共济失调3型的化合物 |
-
2020
- 2020-02-10 AU AU2020222881A patent/AU2020222881C1/en active Active
- 2020-02-10 KR KR1020217028864A patent/KR102907028B1/ko active Active
- 2020-02-10 IL IL285399A patent/IL285399B2/en unknown
- 2020-02-10 CA CA3129067A patent/CA3129067A1/en active Pending
- 2020-02-10 JP JP2021547446A patent/JP7587511B2/ja active Active
- 2020-02-10 PE PE2021001329A patent/PE20220139A1/es unknown
- 2020-02-10 WO PCT/US2020/017430 patent/WO2020167628A1/en not_active Ceased
- 2020-02-10 UA UAA202105103A patent/UA129890C2/uk unknown
- 2020-02-10 BR BR112021015853-7A patent/BR112021015853A2/pt unknown
- 2020-02-10 EA EA202192170A patent/EA202192170A1/ru unknown
- 2020-02-10 MX MX2021009667A patent/MX2021009667A/es unknown
- 2020-02-10 US US17/430,511 patent/US12384797B2/en active Active
- 2020-02-10 SG SG11202108519TA patent/SG11202108519TA/en unknown
- 2020-02-10 CN CN202080028449.2A patent/CN113795304A/zh active Pending
- 2020-02-10 EP EP20714017.9A patent/EP3924049B1/en active Active
-
2021
- 2021-08-12 CO CONC2021/0010598A patent/CO2021010598A2/es unknown
- 2021-08-12 CL CL2021002137A patent/CL2021002137A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220135586A1 (en) | 2022-05-05 |
| AU2020222881B2 (en) | 2025-07-10 |
| EA202192170A1 (ru) | 2021-11-15 |
| EP3924049B1 (en) | 2026-08-12 |
| BR112021015853A2 (pt) | 2021-10-05 |
| CA3129067A1 (en) | 2020-08-20 |
| CN113795304A (zh) | 2021-12-14 |
| US12384797B2 (en) | 2025-08-12 |
| AU2020222881C1 (en) | 2026-01-22 |
| IL285399B2 (en) | 2025-06-01 |
| MX2021009667A (es) | 2021-12-10 |
| AU2020222881A1 (en) | 2021-09-09 |
| WO2020167628A1 (en) | 2020-08-20 |
| KR20210137040A (ko) | 2021-11-17 |
| JP2022520822A (ja) | 2022-04-01 |
| CL2021002137A1 (es) | 2022-02-25 |
| IL285399A (en) | 2021-09-30 |
| KR102907028B1 (ko) | 2026-01-05 |
| SG11202108519TA (en) | 2021-09-29 |
| CO2021010598A2 (es) | 2021-08-30 |
| JP7587511B2 (ja) | 2024-11-20 |
| IL285399B1 (en) | 2025-02-01 |
| EP3924049A1 (en) | 2021-12-22 |
| UA129890C2 (uk) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002137A1 (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. | |
| AR082154A1 (es) | DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4 | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| MX381849B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. | |
| BR112014002675A2 (pt) | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" | |
| ECSP21034668A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| PE20181272A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR088218A1 (es) | Compuestos heterociclicos utiles como inhibidores de pi3k | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| NI201300113A (es) | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas. | |
| UY31638A1 (es) | Furo[3,2-c]piridina y tieno[3,2-c]piridinas | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt |